Pharmicell Co Ltd

005690

Company Profile

  • Business description

    Pharmicell Co Ltd is a biotechnology company, engages in the manufacturing of biopharmaceutical medicines in South Korea. Its biopharmaceutical business engages in the development and manufacture of stem cell therapeutic drugs and stem cell-based cosmetics and others. Its products under development include mesenchymal stem cell products, such as Cellgram_AMI, a heart disease drug; Cellgram_IS and Cellgram_SCI, which are brain/nerve disorder drugs; Cellgram_Lung, a pulmonary disease drug; Cellgram_LC, a liver disease drug; and Cellgram_ED and Cellgram_CLI for the treatment of graft-versus-host disease, kidney transplant, impotence, and critical lower limb ischemia.

  • Contact

    12F Chungho B/D
    3-2 Nonhyun-dong Gangnam-gu
    Seoul135-010
    KOR

    T: +82 234960114

    http://www.pharmicell.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    161

Stocks News & Analysis

stocks

Overvalued ASX mining giant

Solid start to 2026 but shares overvalued.
stocks

Going into earnings, is Microsoft stock a buy, a sell, or fairly valued?

With recent structural changes and strong Azure performance, here’s what we think of Microsoft stock.
stocks

Tesla earnings: Shares fall as market focuses on uncertainty in near term

Are shares overpriced despite the fall?

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,317.2026.50-0.28%
CAC 408,202.7823.00-0.28%
DAX 4024,240.2832.490.13%
Dow JONES (US)47,152.75418.140.89%
FTSE 1009,610.1931.620.33%
HKSE26,160.15192.170.74%
NASDAQ23,200.24258.451.13%
Nikkei 22549,299.65658.041.35%
NZX 50 Index13,391.5914.490.11%
S&P 5006,795.0356.590.84%
S&P/ASX 2009,019.0025.20-0.28%
SSE Composite Index3,950.3127.900.71%

Market Movers